BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lohan C, Diamantopoulos A, LeReun C, Wright E, Bohm N, Sawyer LM. Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation. BMJ Open Gastroenterol 2019;6:e000302. [PMID: 31413856 DOI: 10.1136/bmjgast-2019-000302] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Hernandez-rocha C, Vande Casteele N. JAK inhibitors: current position in treatment strategies for use in inflammatory bowel disease. Current Opinion in Pharmacology 2020;55:99-109. [DOI: 10.1016/j.coph.2020.10.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Vellopoulou K, Stefanou G, Tzanetakos C, Boubouchairopoulou N, Nakou M, Gourzoulidis G, Kourlaba G. Cost-effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Greece. Eur J Gastroenterol Hepatol 2021;33:325-33. [PMID: 32976189 DOI: 10.1097/MEG.0000000000001916] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Shaffer SR, Huang E, Patel S, Rubin DT. Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis. Am J Gastroenterol 2021;116:125-33. [PMID: 32947317 DOI: 10.14309/ajg.0000000000000847] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 D'Amico F, Peyrin-Biroulet L, Danese S. Tofacitinib for Acute Severe Colitis: When the going Gets Tough, the Tough Get Going. J Crohns Colitis 2020;14:883-5. [PMID: 32579173 DOI: 10.1093/ecco-jcc/jjaa028] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 Ng AC. Clinical Efficacy of Tofacitinib in Moderate to Severe Ulcerative Colitis. J Crohns Colitis 2021;15:1774. [PMID: 33822914 DOI: 10.1093/ecco-jcc/jjab062] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Honap S, Chee D, Chapman TP, Patel M, Kent AJ, Ray S, Sharma E, Kennedy J, Cripps S, Walsh A, Goodhand JR, Ahmad T, Satsangi J, Irving PM, Kennedy NA, Begum Y, O’neill R, Mawdsley J, Samaan M, Anderson S, Sanderson J, Gordon C, Prasad S, Lin S, Chanchlani N, Elworthy C, Cairnes V, Travis S, Brain O, Palmer R, Ambrose T, Dubois P, Hayee BH, Chung-faye G, Medcalf L, Begum Y, O’neill R, Mawdsley J, Samaan M, Anderson S, Sanderson J, Gordon C, Prasad S, Lin S, Chanchlani N, Elworthy C, Cairnes V, Travis S, Brain O, Palmer R, Ambrose T, Dubois P, Hayee BH, Chung-faye G, Medcalf L; LEO [London, Exeter, Oxford] IBD Research Consortium. Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience. Journal of Crohn's and Colitis 2020;14:1385-93. [DOI: 10.1093/ecco-jcc/jjaa075] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 8.5] [Reference Citation Analysis]
7 Rogler G. Efficacy of JAK inhibitors in Crohn's Disease. J Crohns Colitis 2020;14:S746-54. [PMID: 31781755 DOI: 10.1093/ecco-jcc/jjz186] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
8 Jairath V, Chan K, Lasch K, Keeping S, Agboton C, Blake A, Patel H. Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis. Expert Rev Gastroenterol Hepatol 2021;15:711-22. [PMID: 33599181 DOI: 10.1080/17474124.2021.1880319] [Reference Citation Analysis]
9 Shivaji UN, Nardone OM, Cannatelli R, Smith SC, Ghosh S, Iacucci M. Small molecule oral targeted therapies in ulcerative colitis. Lancet Gastroenterol Hepatol 2020;5:850-61. [PMID: 32171056 DOI: 10.1016/S2468-1253(19)30414-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
10 Armuzzi A, Liguori G. Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: A narrative review. Dig Liver Dis 2021;53:803-8. [PMID: 33744172 DOI: 10.1016/j.dld.2021.03.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
11 Taxonera C, de Andrés-Nogales F, García-López S, Sánchez-Guerrero A, Menchén B, Peral C, Cábez A, Gómez S, López-Ibáñez de Aldecoa A, Casado MÁ, Menchén L. Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain. Expert Rev Pharmacoecon Outcomes Res 2021;:1-11. [PMID: 33615953 DOI: 10.1080/14737167.2021.1880324] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Li Y, Yao C, Xiong Q, Xie F, Luo L, Li T, Feng P. Network meta‐analysis on efficacy and safety of different Janus kinase inhibitors for ulcerative colitis. Clinical Pharmacy Therapeu. [DOI: 10.1111/jcpt.13622] [Reference Citation Analysis]
13 Gisbert JP, Chaparro M. Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)? J Clin Med 2021;10:5318. [PMID: 34830595 DOI: 10.3390/jcm10225318] [Reference Citation Analysis]